NASDAQ:AMRI - 275218 Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$21.74
+0.30 (1.20%)
Get New 275218 Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMRI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMRI

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for 275218 in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $21.74.
N/A
The current consensus among 0 investment analysts is to n/a stock in 275218. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/14/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/13/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/12/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/10/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/7/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/5/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/7/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/12/2017First AnalysisDowngradeOverweight ➝ Equal WeightLow
i
6/8/2017JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
i
6/6/2017William BlairDowngradeOutperform ➝ Market PerformLow
i
Rating by J. Kreger at William Blair
5/23/2017William BlairReiterated RatingOutperformLow
i
Rating by J. Kreger at William Blair
5/11/2017Morgan StanleyDowngradeOverweight ➝ Equal Weight$18.00High
i
8/5/2016Morgan StanleyReiterated RatingBuy$17.00N/A
i
Rating by Ricky Goldwasser at Morgan Stanley
5/8/2016Morgan StanleyReiterated RatingBuyN/A
i
Rating by Ricky Goldwasser at Morgan Stanley
(Data available from 3/7/2016 forward)
275218 logo
Albany Molecular Research, Inc. is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. The API segment includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates. The DP segment includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized sterile injectable products and ophthalmic formulations. The FC segment includes lab to commercial scale synthesis of reagents and diverse compounds. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.
Read More

Today's Range

Now: $21.74
$21.74
$21.74

50 Day Range

MA: $21.74
$21.74
$21.74

52 Week Range

Now: $21.74
$13.01
$22.17

Volume

N/A

Average Volume

872,120 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of 275218?

The following Wall Street research analysts have issued reports on 275218 in the last twelve months:
View the latest analyst ratings for AMRI.

What is the current price target for 275218?

0 Wall Street analysts have set twelve-month price targets for 275218 in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for 275218 in the next year.
View the latest price targets for AMRI.

What is the current consensus analyst rating for 275218?

275218 currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AMRI.

How do I contact 275218's investor relations team?

275218's physical mailing address is 21 Corporate Cir, PO Box 15098, ALBANY, NY 12203-5154, United States. The biotechnology company's listed phone number is +1-518-4640279. The official website for 275218 is www.amriglobal.com.